The death of cancer? Part 3: Searching for cure or long-term control 18 Feb 2016 In the last instalment of a three-part essay reflecting on five decades of cancer treatment advances, ICR CEO Professor Paul Workman explores the transition from classical chemotherapy drugs to new molecularly targeted treatments and immunotherapy, and discusses the attitudes and language used in the drive to defeat cancer. Find out more Show/Hide
Kinase inhibitors: the science behind a revolution 19 Jul 2013 A little more than a decade ago, the prospects for people with chronic myelogenous leukaemia (CML) were rather bleak. Common treatments included high-risk bone marrow transplants, which required at least four weeks in hospital and often led to severe complications down the line. Find out more Show/Hide